
Parakkal Deepak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9577375/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmunity Reviews, 2022, 21, 102927.	2.5	132
2	Predicting Risk of Surgery in Patients With Small Bowel Crohn's Disease Strictures Using Computed Tomography and Magnetic Resonance Enterography. Inflammatory Bowel Diseases, 2022, , .	0.9	2
3	Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Crohn's & Colitis 360, 2022, 4, otac002.	0.5	28
4	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. American Journal of Gastroenterology, 2022, Publish Ahead of Print, .	0.2	3
5	Reactogenicity of the Messenger <scp>RNA SARS</scp> – <scp>CoV</scp> â€2 Vaccines Associated With Immunogenicity in Patients With Autoimmune and Inflammatory Disease. Arthritis Care and Research, 2022, 74, 1953-1960.	1.5	5
6	Tools for the Diagnosis and Management of Crohn's Disease. Gastroenterology Clinics of North America, 2022, 51, 213-239.	1.0	2
7	Management of refractory inflammatory bowel disease. Current Opinion in Gastroenterology, 2022, 38, 347-357.	1.0	6
8	Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clinical Gastroenterology and Hepatology, 2021, 19, 2207-2209.e3.	2.4	20
9	Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 66, 3563-3569.	1.1	3
10	Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1592-1601.e3.	2.4	69
11	A TRANSLATIONAL PHASE I STUDY OF TAUROURSODEOXYCHOLIC ACID (TUDCA) TO REDUCE SYMPTOMS AND ER STRESS IN ACTIVE ULCERATIVE COLITIS. Gastroenterology, 2021, 160, S8.	0.6	0
12	MRE Evaluation of Intestinal Inflammation. Topics in Magnetic Resonance Imaging, 2021, 30, 13-22.	0.7	3
13	Medical and Endoscopic Management of Crohn Disease. Topics in Magnetic Resonance Imaging, 2021, 30, 43-61.	0.7	0
14	Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Disease Outcome and Response to Therapy. Journal of Crohn's and Colitis, 2021, 15, 1431-1442.	0.6	39
15	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine, 2021, 27, 717-726.	15.2	838
16	<i>Debaryomyces</i> is enriched in Crohn's disease intestinal tissue and impairs healing in mice. Science, 2021, 371, 1154-1159.	6.0	126
17	Multidisciplinary management of perianal Crohn's disease. Current Opinion in Gastroenterology, 2021, 37, 295-305.	1.0	7
18	Inflammatory Bowel Disease, Celiac Disease, and Primary Sclerosing Cholangitis: Is There a Link?. Gastroenterology, 2021, 160, 2207.	0.6	1

#	Article	IF	CITATIONS
19	P584 Mucosal Eosinophilia is an Independent Predictor of Vedolizumab Effectiveness in Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, S537-S537.	0.6	0
20	Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 1698-1702.	0.9	10
21	Sa511 INFLAMMATORY BOWEL DISEASES ARE ASSOCIATED WITH AN INCREASED RISK OF INCIDENT CARDIOVASCULAR DISEASE AND RELATED DEATH: A PROPENSITY MATCHED ANALYSIS OF THE UNITED KINGDOM BIOBANK STUDY. Gastroenterology, 2021, 160, S-529.	0.6	0
22	388 HIGHER VISCERAL ADIPOSE TISSUE IS ASSOCIATED WITH LOWER RATES OF STEROID-FREE DEEP AND ENDOSCOPIC REMISSION IN PATIENTS STARTING BIOLOGIC THERAPY FOR INFLAMMATORY BOWEL DISEASES: RESULTS FROM THE CONSTELLATION STUDY. Gastroenterology, 2021, 160, S-79.	0.6	1
23	Sa542 INITIAL RESULTS FROM A MULTICENTER PROSPECTIVE REGISTRY EVALUATING POUCH-RELATED OUTCOMES. Gastroenterology, 2021, 160, S-542.	0.6	0
24	Sa486 PATIENTS WITH PENETRATING AND/OR STRICTURING CROHN'S DISEASE HAVE A HIGHER REPORTED PREVALENCE OF ACTIVE INTESTINAL AND EXTRA-INTESTINAL SYMPTOMS, SURGERIES AND NEED FOR BIOLOGICS: ANALYSIS OF THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT WITH IBD. Gastroenterology, 2021, 160, S-517-S-518.	0.6	0
25	Su605 QUANTIFICATION OF INTESTINAL PERMEABILITY IN HUMAN CROHN'S DISEASE: A PRELUDE TO SPECIMEN-FREE, NON-INVASIVE ASSESSMENT OF HUMAN GUT BARRIER INTEGRITY USING PYRAZINE DERIVED FLUOROPHORES. Gastroenterology, 2021, 160, S-753.	0.6	0
26	244 A SYSTEMATIC REVIEW OF THE DIAGNOSTIC CRITERIA, EFFICACY AND SAFETY OUTCOMES REPORTED IN STUDIES OF TREATMENT OF IMMUNE CHECKPOINT INHIBITOR COLITIS. Gastroenterology, 2021, 160, S-53.	0.6	0
27	Su450 EFFECTIVENESS AND SAFETY OF COMBINING BIOLOGICS AND/OR SMALL MOLECULES IN INFLAMMATORY BOWEL DISEASES: SYSTEMATIC REVIEW WITH META-ANALYSIS. Gastroenterology, 2021, 160, S-696.	0.6	3
28	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. Annals of Internal Medicine, 2021, 174, 1572-1585.	2.0	273
29	Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease. Gastroenterology, 2021, 161, 394-399.	0.6	27
30	S967 The Correlation Between Visceral Abdominal and Total Adipose Tissue With Metabolic Risk Factors in Patients With Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2021, 116, S463-S463.	0.2	0
31	S733 Novel Cytokine Signature Predicts Acute Intestinal Inflammation Identified on Magnetic Resonance Enterography in Crohn's Disease: A Role for IL-8, IL-10, IP-10, and MCP. American Journal of Gastroenterology, 2021, 116, S335-S336.	0.2	0
32	S933 Risk Factors for Cardiovascular Diseases in Participants With Inflammatory Bowel Diseases: Analysis of the United Kingdom Biobank. American Journal of Gastroenterology, 2021, 116, S443-S443.	0.2	1
33	Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance. The Lancet Gastroenterology and Hepatology, 2021, 6, 884-885.	3.7	11
34	Evaluation of Nonalcoholic Fatty Liver Disease in Pediatric Patients With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2021, 72, 574-578.	0.9	4
35	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitors. Med, 2021, 2, 1327-1341.e4.	2.2	31
36	Editorial: use of intestinal ultrasound in the scoring of Crohn's disease activity in clinical trials—is it ready for prime time yet?. Alimentary Pharmacology and Therapeutics, 2021, 53, 946-947.	1.9	1

#	Article	IF	CITATIONS
37	Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1089-1097.	0.9	19
38	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1917-1925.	0.9	11
39	Reversing the Tide: Improving the Recruitment of Patients With Inflammatory Bowel Disease in Clinical Trials in the United States. Crohn's & Colitis 360, 2020, 2, .	0.5	0
40	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. Crohn's & Colitis 360, 2020, 2, otaa039.	0.5	8
41	Tu1899 REAL-WORLD EFFECTIVENESS AND SAFETY OF TOFACITINIB IN CROHN'S DISEASE: A MULTI-CENTER STUDY. Gastroenterology, 2020, 158, S-1211.	0.6	1
42	S0897 Efficacy and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2020, 115, S461-S462.	0.2	4
43	Mo1887 IMPACT OF TUMOR NECROSIS FACTOR ALPHA ANTAGONISTS ON LIVER FAT AND BODY COMPOSITION MEASURED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH CROHN'S DISEASE. Gastroenterology, 2020, 158, S-963-S-964.	0.6	0
44	Postprandial Chylomicron Output and Transport Through Intestinal Lymphatics Are Not Impaired in Active Crohn's Disease. Gastroenterology, 2020, 159, 1955-1957.e2.	0.6	4
45	Mo1909 EVALUATION OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Gastroenterology, 2020, 158, S-973-S-974.	0.6	0
46	Su1858 SEVERITY OF HEPATIC STEATOSIS AND THIOPURINE USE INCREASE THE RISK OF DRUG INDUCED LIVER INJURY IN CROHN'S DISEASE. Gastroenterology, 2020, 158, S-677-S-678.	0.6	0
47	Pouchitis: Bile Acid Deficiency Links Inflammation to Dysbiosis. Gastroenterology, 2020, 159, 1615-1616.	0.6	1
48	Sa1865 ASSOCIATION BETWEEN VEDOLIZUMAB LEVELS, ANTI-VEDOLIZUMAB LEVELS AND ENDOSCOPIC HEALING INDEX IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES. Gastroenterology, 2020, 158, S-456-S-457.	0.6	0
49	Su1918 CROHN'S DISEASE SMALL BOWEL STRICTURES: DEVELOPMENT AND RISK FOR SURGERY IN PATIETNS WITH SMALL BOWEL CROHN'S DISEASE. Gastroenterology, 2020, 158, S-702.	0.6	0
50	347 SERUM METABOLOMIC APPROACH IDENTIFIES SECONDARY BILE ACIDS GLYCOCHOLIC ACID AND GLYCOURSODEOXYCHOLIC ACID AS PREDICTIVE OF CROHN'S DISEASE CLINICAL RESPONSE TO VEDOLIZUMAB. Gastroenterology, 2020, 158, S-62.	0.6	0
51	Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis—one more arrow in the quiver of nonâ€invasive diagnostics. Alimentary Pharmacology and Therapeutics, 2020, 52, 401-402.	1.9	1
52	Imaging Findings of Ileal Inflammation at Computed Tomography and Magnetic Resonance Enterography: What do They Mean When Ileoscopy and Biopsy are Negative?. Journal of Crohn's and Colitis, 2020, 14, 455-464.	0.6	23
53	Reply to the Letter to the Editor: Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, e46-e46.	0.9	1
54	Melanoma and non-Melanoma Skin Cancer in Inflammatory Bowel Disease Patients following Tumor Necrosis Factor-α Inhibitor Monotherapy and in Combination with Thiopurines: Analysis of the Food and Drug Administration Adverse Event Reporting System. Journal of Gastrointestinal and Liver Diseases, 2020, 23, 267-271.	0.5	52

#	Article	IF	CITATIONS
55	P083 CREATION OF A PROSPECTIVE, LONGITUDINAL ADULT INFLAMMATORY BOWEL DISEASE COHORT COMBINING HIGH-RESOLUTION PHENOTYPING WITH BIOSAMPLE COLLECTION TO FACILITATE PRECISION MEDICINE: SPARC IBD. Gastroenterology, 2020, 158, S117.	0.6	0
56	Editorial: crystal gazing with magnetic resonance enterography to predict the response to TNFâ€alpha inhibitors in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1531-1532.	1.9	0
57	Novel Imaging Approaches in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2019, 25, 248-260.	0.9	13
58	Improving Vaccination Adherence in Inflammatory Bowel Diseases. Gastroenterology, 2019, 157, e35.	0.6	2
59	The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 447-470.	0.6	34
60	Mo1474 – Low Vitamin D Correlates with Primary Scelorisng Cholangitis Disease Severity in Patients with Coexistent Ulcerative Colitis. Gastroenterology, 2019, 156, S-1319.	0.6	0
61	Sa1854 – Impact of Bariatric Surgery on the Long-Term Clinical Course of Inflammatory Bowel Diseases. Gastroenterology, 2019, 156, S-429.	0.6	Ο
62	Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. Clinical Gastroenterology and Hepatology, 2019, 17, 2816-2818.	2.4	19
63	796 – Real-World Effectiveness of Tofacitinib in Ulcerative Colitis; a Multi-Center Study. Gastroenterology, 2019, 156, S-168-S-169.	0.6	5
64	Mo1888 – Improvement in Radiographic Small Bowel Inflammation and Starting an Anti-Integrin Leads to Worsening Hepatic Steatosis in Crohn's Disease. Gastroenterology, 2019, 156, S-875.	0.6	0
65	Tu1828 – Enhancing Utilization of Therapeutic Drug Monitoring in Inflammatory Bowel Disease Correlates with Improved Outcomes. Gastroenterology, 2019, 156, S-1140-S-1141.	0.6	1
66	797 – Real-World Safety of Tofacitinib in Inflammatory Bowel Diseases: A Multi-Center Study. Gastroenterology, 2019, 156, S-169.	0.6	3
67	Sa1838 – Nonalcoholic Fatty Liver Disease with Advanced Fibrosis is Associated with Increased Risk of Rescue Corticosteroid Use, Hospitalizations and Surgeries in Crohn's Disease. Gastroenterology, 2019, 156, S-422-S-423.	0.6	0
68	660 – Improving Vaccination Adherence in Inflammatory Bowel Diseases (Poster Presentation). Gastroenterology, 2019, 156, S-139-S-140.	0.6	0
69	Magnetic resonance enterography features of small bowel Crohn's disease activity: an inter-rater reliability study of small bowel active inflammation in clinical practice setting. British Journal of Radiology, 2019, 92, 20180930.	1.0	10
70	P084 AN EVALUATION OF THE CLINICAL COURSE AND UTILIZATION PATTERNS FOR ACUTE AND CHRONIC POUCH-RELATED CONDITIONS AMONG PATIENTS TREATED IN A MULTICENTER COHORT. Gastroenterology, 2019, 156, S57-S58.	0.6	0
71	Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. Inflammatory Bowel Diseases, 2019, 25, 1569-1576.	0.9	50
72	P407 Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study. Journal of Crohn's and Colitis, 2019, 13, S312-S313.	0.6	0

#	Article	IF	CITATIONS
73	P344 Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study. Journal of Crohn's and Colitis, 2019, 13, S274-S275.	0.6	13
74	Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab. Inflammatory Bowel Diseases, 2019, 25, e87-e88.	0.9	21
75	Multiphase Computed Tomographic Enterography: Diagnostic Yield and Efficacy in Patients With Suspected Small Bowel Bleeding. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 438-447.	1.2	10
76	Volvulus of the ileal pouch–anal anastomosis: a meta-narrative systematic review of frequency, diagnosis, and treatment outcomes. Gastroenterology Report, 2019, 7, 403-410.	0.6	17
77	784 A Population-Based Analysis of Obesity, Metabolic Syndrome, and Cardiovascular Outcomes Among Patients With Inflammatory Bowel Disease in the National Health and Nutrition Examination Survey 2009-2010. American Journal of Gastroenterology, 2019, 114, S454-S454.	0.2	1
78	1108 Alkaline Phosphatase Levels Are Negatively Correlated With the Severity of Hepatic Steatosis in Patients With Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, S624-S625.	0.2	0
79	Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty. Journal of Crohn's and Colitis, 2019, 13, 182-188.	0.6	23
80	Ustekinumab Is Effective for the Treatment of Crohn's Disease of the Pouch in a Multicenter Cohort. Inflammatory Bowel Diseases, 2019, 25, 767-774.	0.9	60
81	Beyond the Label: Ensuring That Drug Benefits Outweigh Risks in the Food and Drug Administration's Risk Evaluation and Mitigation Strategy Program. American Journal of Gastroenterology, 2019, 114, 1017-1019.	0.2	1
82	686 Neither Obesity nor Hepatic Steatosis Are Associated With an Increased Prevalent or Incident Colonic Dysplasia in Patients With Inflammatory Bowel Disease and Concomitant Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, S402-S403.	0.2	0
83	783 Nonalcoholic Fatty Liver Disease in a South Asian Crohn's Disease Population: External Validation of the St. Louis Steatosis Index. American Journal of Gastroenterology, 2019, 114, S453-S454.	0.2	1
84	Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 1815-1825.	0.9	16
85	De-novo Inflammatory Bowel Disease After Bariatric Surgery: A Large Case Series. Journal of Crohn's and Colitis, 2018, 12, 452-457.	0.6	29
86	Diffusion-weighted MRI in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2018, 3, 433-443.	3.7	21
87	Bariatric Surgery Is Acceptably Safe in Obese Inflammatory Bowel Disease Patients: Analysis of the Nationwide Inpatient Sample. Obesity Surgery, 2018, 28, 1007-1014.	1.1	27
88	P165 UTILIZATION OF REACTIVE DRUG LEVEL MONITORING IN INFLAMMATORY BOWEL DISEASE. Gastroenterology, 2018, 154, S88.	0.6	0
89	Mucinous Small Bowel Adenocarcinoma Mimicking Change to Internal Penetrating Phenotype in Well-controlled Crohn's Disease. American Journal of Gastroenterology, 2018, 113, 1732-1733.	0.2	2
90	Role of Abdominal Imaging in the Diagnosis of IBD Strictures, Fistulas, and Postoperative Complications. , 2018, , 79-95.		0

#	Article	IF	CITATIONS
91	Sa1988 - Crohn's Disease Patients have an Increased Risk of Nonalcoholic Fatty Liver Disease: A Case-Control Study using MRI Proton Density Fat Fraction Mapping. Gastroenterology, 2018, 154, S-438.	0.6	0
92	160 - Anti-TNF Inhibitors are not Associated with Increased Risk of Infection after Joint Replacement Surgery. Gastroenterology, 2018, 154, S-44-S-45.	0.6	0
93	Mo1900 - Vedolizumab for the Treatment of Pouchitis. Gastroenterology, 2018, 154, S-844-S-845.	0.6	0
94	Sa1805 - Outcomes after Joint Replacement Surgery in Patients with Inflammatory Bowel Disease. Gastroenterology, 2018, 154, S-401-S-402.	0.6	1
95	Phenotype and Clinical Course of Inflammatory Bowel Disease With Co-existent Celiac Disease. Journal of Crohn's and Colitis, 2018, 12, 973-980.	0.6	19
96	Impact of a Standardized Reporting System for Magnetic Resonance Enterography on Small Bowel Crohn's Disease Management. American Journal of Gastroenterology, 2018, 113, S331.	0.2	0
97	Crohn's disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. Abdominal Radiology, 2017, 42, 1068-1086.	1.0	17
98	Isolated Acute Terminal Ileitis Without Preexisting Inflammatory Bowel Disease Rarely Progresses to Crohn's Disease. Digestive Diseases and Sciences, 2017, 62, 3557-3562.	1.1	18
99	Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Gastroenterology Clinics of North America, 2017, 46, 603-626.	1.0	47
100	Genome-Wide Search Identified Genetic Variants that can Predict TNF Antagonist Responsiveness in Inflammatory Bowel Disease Patients. Gastroenterology, 2017, 152, S78-S79.	0.6	0
101	Bariatric Surgery is Safe in Obese Inflammatory Bowel Disease Patients. Gastroenterology, 2017, 152, S136.	0.6	0
102	De-Novo Inflammatory Bowel Disease after Bariatric Surgery: A Novel Association. Gastroenterology, 2017, 152, S366-S367.	0.6	0
103	Impact of Bariatric Surgery on the Natural History of Inflammatory Bowel Disease. Gastroenterology, 2017, 152, S367.	0.6	0
104	Genetic Risk Burden Affects Inflammatory Bowel Disease Perianal Behavior and Response to TNF Antagonists. Gastroenterology, 2017, 152, S982-S983.	0.6	0
105	Transmural Healing and MRI Remission. Inflammatory Bowel Diseases, 2017, 23, E44-E45.	0.9	5
106	Natural History and Phenotype of Inflammatory Bowel Disease with Co-Existent Celiac Disease. Gastroenterology, 2017, 152, S378.	0.6	0
107	Vitamin D Deficiency Correlates With Primary Sclerosing Cholangitis Disease Severity in Patients With Coexistent Ulcerative Colitis. American Journal of Gastroenterology, 2017, 112, S514-S515.	0.2	0
108	Assessment of Gender and Racial Disparities in Quality of Care Indicators for Inflammatory Bowel Disease. American Journal of Gastroenterology, 2017, 112, S604.	0.2	0

#	Article	IF	CITATIONS
109	Inflammatory Bowel Diseases Dedicated Gastroenterologists Have Greater Adherence to Clinical Care Quality Indicators Than General Gastroenterologists. American Journal of Gastroenterology, 2017, 112, S349-S350.	0.2	0
110	Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. Drug Design, Development and Therapy, 2016, Volume 10, 3685-3698.	2.0	38
111	P-113 Yl Body Fat and Skeletal Muscle Composition Differs in Crohn's Disease Patients Depending on Radiological Response to Medical Therapy. Inflammatory Bowel Diseases, 2016, 22, S45.	0.9	0
112	Sa1927 Natural History of Isolated Terminal Ileitis in Patients Without an Existing Diagnosis of Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S406.	0.6	1
113	Tu1936 Natural History of Radiological Transmural Response Identified on Serial Enterography in Small Bowel Crohn's Disease Patients. Gastroenterology, 2016, 150, S982-S983.	0.6	0
114	Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease. American Journal of Gastroenterology, 2016, 111, 997-1006.	0.2	111
115	Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease. Inflammatory Bowel Diseases, 2016, 22, 2280-2288.	0.9	37
116	628 Natural History of Radiological Transmural Healing in Small Bowel Crohn's Disease Patients Undergoing Serial Enterography. Gastroenterology, 2016, 150, S130-S131.	0.6	1
117	Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. Gastrointestinal Endoscopy, 2016, 83, 1005-1012.	0.5	39
118	Utility and Safety of Balloon-Assisted Enteroscopy in Small Bowel Crohn's Disease: Single - Center Cohort Experience. American Journal of Gastroenterology, 2016, 111, S304.	0.2	0
119	Radiological and Clinical Parameters in Crohn's Disease Patients as Predictors of Response to Medical Therapy. American Journal of Gastroenterology, 2015, 110, S807-S808.	0.2	0
120	Update on the Medical Management of Crohn's Disease. Current Gastroenterology Reports, 2015, 17, 41.	1.1	8
121	Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatology International, 2015, 35, 661-668.	1.5	15
122	Risk of Myeloid Neoplasms in Inflammatory Bowel Disease Patients Is Linked to Exposure to Thiopurines and Not With Tumor Necrosis Factor-alpha Inhibitors. Clinical Gastroenterology and Hepatology, 2015, 13, 1857-1858.	2.4	1
123	Radiological Response Is Associated With Better Long-Term Outcomes and Is a Potential Treatment Target in Patients With Small Bowel Crohn's Disease: ACG Fellows-In-Training Award. American Journal of Gastroenterology, 2015, 110, S786.	0.2	0
124	Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 40, 1035-1043.	1.9	35
125	Radiographical evaluation of ulcerative colitis. Gastroenterology Report, 2014, 2, 169-177.	0.6	33
126	Effect of Tumor Necrosis Factor–α Inhibitors on Drug-Induced Pancreatitis in Inflammatory Bowel Disease. Annals of Pharmacotherapy, 2014, 48, 1282-1287.	0.9	11

#	Article	IF	CITATIONS
127	Clinical Characteristics and Natural History of Crohn's Disease Patients With Endoscopic Skipping of Distal Terminal Ileum on Ileoscopy. American Journal of Gastroenterology, 2014, 109, S495-S496.	0.2	1
128	Endoscopic Skipping of the Distal Terminal IIeum in Pediatric Crohn's Disease. American Journal of Gastroenterology, 2014, 109, S498.	0.2	0
129	Simulated Comparison of Topical and Oral Formulations of 5-Aminosalicylate for the Treatment of Ulcerative Colitis. Inflammatory Bowel Diseases, 2013, 19, 301-308.	0.9	3
130	Increased risk of osteoporosis-related fractures in patients with irritable bowel syndrome. Osteoporosis International, 2013, 24, 1169-1175.	1.3	33
131	Concomitant antibiotic usage does not augment the risk of inflammatory bowel disease with isotretinoin treatment for acne: a review of the Food and Drug Administration Adverse Event Reporting System. European Journal of Clinical Pharmacology, 2013, 69, 1041-1042.	0.8	0
132	Ischaemic Colitis in Rheumatoid Arthritis Patients Receiving Tumour Necrosis Factor-α Inhibitors: An Analysis of Reports to the US FDA Adverse Event Reporting System. Drug Safety, 2013, 36, 329-334.	1.4	14
133	Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System. Alimentary Pharmacology and Therapeutics, 2013, 38, 388-396.	1.9	81
134	Alleged isotretinoin-associated inflammatory bowel disease: Disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. Journal of the American Academy of Dermatology, 2013, 69, 393-398.	0.6	28
135	T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study. American Journal of Gastroenterology, 2013, 108, 99-105.	0.2	193
136	Ischemic Colitis with Type I Interferons Used in the Treatment of Hepatitis C and Multiple Sclerosis: An Evaluation from the Food and Drug Administration Adverse Event Reporting System and Review of the Literature. Annals of Pharmacotherapy, 2013, 47, 537-542.	0.9	15
137	The Metoclopramide Black Box Warning for Tardive Dyskinesia: Effect on Clinical Practice, Adverse Event Reporting, and Prescription Drug Lawsuits. American Journal of Gastroenterology, 2013, 108, 866-872.	0.2	68
138	Relationship Between Mesenteric Abnormalities on Computed Tomography and Malignancy. Journal of Clinical Gastroenterology, 2013, 47, 409-414.	1.1	27
139	Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clinical and Experimental Gastroenterology, 2013, 6, 43.	1.0	30
140	An Analysis of Hospital Charges and Length of Stay in Patients with Eosinophilic Esophagitis Admitted for Foreign Body in the Esophagus. American Journal of Gastroenterology, 2013, 108, S12-S13.	0.2	2
141	Comorbidity with Depression Is Associated with Increased Length of Stay and Higher Hospitalization Charges in Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, S519-S520.	0.2	1
142	Lubiprostone induced ischemic colitis. World Journal of Gastroenterology, 2013, 19, 299.	1.4	17
143	Safety of Polyethylene Glycol-based Preparations for Bowel Cleansing before Colonoscopy: An Analysis of the Food and Drug Administration Adverse Event Reporting System. American Journal of Gastroenterology, 2013, 108, S591.	0.2	0
144	Analysis of Drug-induced Liver Injury Reported with Tumor Necrosis Factor-alpha Inhibitors to the Food and Drug Administration Adverse Event Reporting System in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, S513.	0.2	0

#	Article	IF	CITATIONS
145	Marked Improvement in Severe and Refractory Formalin Colitis with Retinyl Palmitate Suppositories. American Journal of Gastroenterology, 2013, 108, S375-S376.	0.2	0
146	Effect of Comorbid Celiac Disease on Hospitalized Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, S519.	0.2	4
147	Analysis of the Food and Drug Administration Adverse Event Reporting System to Examine the Relationship between Tumor Necrosis Factor Alpha Inhibitor Therapy and Congestive Heart Failure among Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, S520-S521.	0.2	0
148	Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. Journal of Gastrointestinal and Liver Diseases, 2013, 22, 269-76.	0.5	23
149	Duodenal diverticulitis: a rare cause of abnormal liver function tests. Endoscopy, 2012, 44, E252-E253.	1.0	Ο
150	Do Gastroenterologists Adhere to Diagnostic and Treatment Guidelines for Celiac Disease?. Journal of Clinical Gastroenterology, 2012, 46, e12-e20.	1.1	16
151	Use of Polyethylene Glycol-based Colonoscopy Preparations Before Rectal Argon Plasma Coagulation. Journal of Clinical Gastroenterology, 2012, 46, 803-804.	1.1	3
152	The Role of Gender in the Occurrence of Comorbidities in Patients with Irritable Bowel Syndrome (IBS): Analysis of the Nationwide Inpatient Sample (NIS) 2008: Presidential Poster. American Journal of Gastroenterology, 2012, 107, S705-S706.	0.2	0
153	Infection Rates with Infliximab in Inflammatory Bowel Disease Compared to Rheumatologic Diseases: A Single Center Experience. American Journal of Gastroenterology, 2012, 107, S662.	0.2	Ο
154	Tumor Necrosis Factor-Alpha Blockers do not Augment the Risk of Viral Infection in Inflammatory Bowel Disease (IBD): A Review of the Food and Drug Administration Adverse Event Reporting System (FDA AERS). American Journal of Gastroenterology, 2012, 107, S636-S637.	0.2	0
155	Ischemic Colitis During Type I Interferon Therapy for Hepatitis C and Multiple Sclerosis. American Journal of Gastroenterology, 2012, 107, S210.	0.2	Ο
156	Disproportionate Lawyer Reporting of Inflammatory Bowel Disease Cases with Isotretinoin: A Review of the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). American Journal of Gastroenterology, 2012, 107, S638-S639.	0.2	0
157	Ischemic Colitis During Treatment with Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis. American Journal of Gastroenterology, 2012, 107, S208.	0.2	Ο
158	New-Onset Inflammatory Bowel Disease During Tumor Necrosis Factor-Alpha Inhibitor Therapy for Rheumatoid Arthritis and Juvenile Rheumatoid Arthritis: A Review of the Food and Drug Administration Adverse Event Reporting System and Literature. American Journal of Gastroenterology, 2012, 107, S621-S622.	0.2	0
159	Increased Risk of Osteoporosis Related Fractures in Patients with Irritable Bowel Syndrome: Presidential Poster. American Journal of Gastroenterology, 2012, 107, S702.	0.2	Ο
160	Concomitant Antibiotic Usage Does Not Further Increase the Risk of Inflammatory Bowel Disease with Isotretinoin Treatment for Acne: A Review of the Food and Drug Administration Adverse Event Reporting System. American Journal of Gastroenterology, 2012, 107, S645.	0.2	0
161	Preventing Patients with Crohn's Disease from Discontinuing Infliximab: A Dynamic Survival Model. American Journal of Gastroenterology, 2012, 107, S651.	0.2	0
162	Tumor Necrosis Factor-alpha Blocker Monotherapy or In Combination with Immunomodulators or Systemic Corticosteroids Does not Augment the Risk of Bacterial Infections: A Review of the Food and Drug Administration Adverse Event Reporting System (FDA AERS). American Journal of Gastroenterology, 2012, 107, S650.	0.2	0

#	Article	IF	CITATIONS
163	Method for the Current Review. Disease-a-Month, 2011, 57, 456.	0.4	Ο
164	Diarrhea. Disease-a-Month, 2011, 57, 490-510.	0.4	10
165	Constipation. Disease-a-Month, 2011, 57, 511-517.	0.4	7
166	Other Effects on the Colon. Disease-a-Month, 2011, 57, 518-523.	0.4	1
167	Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy. European Journal of Gastroenterology and Hepatology, 2011, 23, 1150-1156.	0.8	100
168	Renal risks of sodium phosphate tablets for colonoscopy preparation: a review of adverse drug reactions reported to the US Food and Drug Administration. Colorectal Disease, 2011, 13, e270-e275.	0.7	20
169	Esophageal Small Cell Carcinoma with Synchronous Renal Cell Carcinoma: A Case Report with Review of the Literature. Case Reports in Gastroenterology, 2011, 5, 196-200.	0.3	4
170	Ischemic colitis masquerading as colonic tumor: Case report with review of literature. World Journal of Gastroenterology, 2011, 17, 5324.	1.4	11
171	Lower body weight and female gender: Hyperphosphatemia risk factors after sodium phosphate preparations. World Journal of Gastroenterology, 2011, 17, 2681.	1.4	1
172	Calcium Phosphate Nephropathy From Colonoscopy Preparations: Effect of Body Weight. American Journal of Gastroenterology, 2010, 105, 705.	0.2	9
173	Safety and Effectiveness of Combining Biologics and Small Molecules in IBD: Systematic Review With Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	1
174	A new way to assess the trajectory of remission in Crohn's disease: Correlating drug levels with a non-invasive blood-biomarker of mucosal remission. Crohn's & Colitis 360, 0, , .	0.5	0